セッション詳細
[PC1]企業ポスター
2026年3月2日(月) 18:30 〜 19:30
企業ポスター・展示(大輪田ホワイエ)
[PC1-01]mRNA治療薬の革新技術
- saRNAおよびHARNATM,最新のmRNA配列最適化 -
Advanced technologies for mRNA-based therapeutics
- saRNA and HARNATM, new mRNA optimizing -
*Ken Miyajima1, Akiko Yanagiya1, Rena Akahori2, Tomohiro Sawadaishi1, Aoi Onuma1, Yanwen Feng1, Satoshi Abe1, Jun Nihira1, Tetsuo Yoshida1, Kazuyuki Nakashima1 (1. ARCALIS, Inc. (Japan), 2. Hitachi, Ltd., Research development group (Japan))
[PC1-02]バイオプロセスサポート製品・技術の展示
Exibition for Bioprocess support materials
*Yoshiaki Ogawa1, Sadao Ozawa1, Yasuhiko Kurisu1, Yosuke Imamura1 (1. Merck Ltd. (Japan))
[PC1-03]経鼻ワクチンとその噴霧デバイスの開発
Formulation development of Intranasal Vaccine and design of spray device for Intranasal Vaccine
*Shota Masuda1, Yasuyuki Shiraishi1, Taiji Horita1, Takashi Kamishita2, Natsumi Kodake2, Toshiaki Takagi2, Takashi Miyazaki2 (1. Taisei Kako Co.,Ltd. (Japan), 2. TOKO YAKUHIN KOGYO CO., LTD. (Japan))
[PC1-04]ニードルフリー表皮内投与 PassPort マイクロポレーション装置 を用いた経皮ワクチンシステム
Transdermal Vaccination System using a Needle-free Intraepidermal Administration, PassPort Microporation Device
*Hirotoshi Adachi1,2, Uros Kascak1 (1. PassPort Technologies, Inc. (USA), 2. PassPort Technologies Japan, Inc. (Japan))
[PC1-05]臨床研究サービスのご紹介
Clinical research service introduction
*Akira Ikeda1 (1. EPS Corporation (Japan))
[PC1-06]粉末経鼻製剤投与基盤技術「SMART」を活用したワクチン開発基盤
SMART (Simple MucoAdhesive Release Technology) as a Platform for Nasal Vaccine Development
*Satoshi Nakano1, Yo Sonoda1, Ryota Ise1 (1. TR Business Division, Shin Nippon Biomedical Laboratories, Ltd. (Japan))
[PC1-07]弊社製品群の紹介（CHO細胞一過性発現培地、エムポックスウイルス核酸キット ジーンキューブMPXV）
Product introduction (Transient expression medium for CHO cells, Mpox virus detection kit: GENECUBE MPXV)
*波多 宏幸1
*Hiroyuki Hata1 (1. Kyokuto pharmaceutical industrial Co., Ltd. (Japan))
*Hiroyuki Hata1 (1. Kyokuto pharmaceutical industrial Co., Ltd. (Japan))
[PC1-08]検査キットメーカー アドテック㈱のご紹介
Introduction to Adtec Co., Ltd. — A Diagnostic Test Kit Manufacturer
*木田 祐一郎1
*Yuichiro Kida1, Kenta Fukuda1, Nobiko Takayama1, Takateru Nozaki1, MIsako Iwai1, Kaoru Kobayashi1, Katsuyoshi Takayama1 (1. Research and Development Department, ADTEC Co.,LTD (Japan))
*Yuichiro Kida1, Kenta Fukuda1, Nobiko Takayama1, Takateru Nozaki1, MIsako Iwai1, Kaoru Kobayashi1, Katsuyoshi Takayama1 (1. Research and Development Department, ADTEC Co.,LTD (Japan))
[PC1-09]次世代を見据えたワクチン抗原製造プラットフォーム：カイコ‐バキュロウイルス発現系の取り組み
Toward next-generation vaccine antigens: a silkworm–baculovirus expression platform
*Tomoki Sasaki1, Keiichi Esaki1, Yo Nakahara1, Masahiro Taniguchi1 (1. KAICO Ltd. (Japan))
[PC1-10]企業紹介
Company introduction
*Akihito Sawada1, Yuusuke Okada1, Takeru Yamakawa1 (1. Infectious Disease Control Labs, Drug Discovery Department Meiji Seika Pharma Co., Ltd. (Japan))
[PC1-11]コモンマーモセットのご紹介
Introduction to the Common Marmoset
*Hiroshi Ikeda1 (1. CLEA-Japan,Inc. (Japan))
[PC1-12]Global Biopharma Index 2025に見る製造の機動性（Manufacturing Agility）課題
Global Biopharma Index 2025 - Manufacturing Agility
*Kensuke Ono1, Mitsuyasu Miwa1 (1. Global LifeScience Technologies Japan (Japan))
[PC1-14]世界最高レベルの無菌注射剤バイアル充填ライン
World highest level aseptic parenteral viall filling system.
*ZENYA YANASE1 (1. Steri Japan Co.Ltd (Japan))
[PC1-15]RTU(Ready to use)シリンジラインのご紹介
Introducing the RTU (Ready to use) syringe line
*Seiji Fukuoka1 (1. HIKARI Pharmaceutical CO.,LTD (Japan))
[PC1-16]Vaccine Business in Daiichi Sankyo
*Ryuji Hashimoto1 (1. Daiichi Sankyo Co., Ltd. Vaccine Business Department (Japan))